Sanofi Financials - Benzinga

Sanofi SA

SNYNASDAQ

Trade with Public

Trade with Public

$40.66

-0.52-1.27%

Dern. MÀJ: Sep 29, 9:59 AM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Dividendes Comparer Options Rapport sur les stocks

Sanofi Financials

Sanofi (SNY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full details on earnings and 2026 outlook.

Vandana Singh

PRO
Sanofi Sees FY2026 Sales $55.789B vs $55.850B Est

Sanofi (NASDAQ:SNY) sees FY2026 sales of $55.789 billion vs $55.850 billion analyst estimate.

Benzinga Newsdesk

PRO
Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B Estimate

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.09 by 11.01 percent. This is a 34.44 percent increase over earnings of $0.90 per share from the same

Benzinga Newsdesk

Why Novavax Stock Is Trading Higher On Wednesday?

Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape outlook amid shift to net loss.

Vandana Singh

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.

Vandana Singh

FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat

Sanofi, Regeneron win FDA nod for Dupixent in pediatric CSU as Q1 sales beat estimates, driven by strong Dupixent growth.

Vandana Singh

© 2026 Benzinga | All Rights Reserved